Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $113
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Equal-Weight rating on DexCom (NASDAQ:DXCM) but lowers the price target from $138 to $113.
July 29, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays analyst Matt Miksic maintains an Equal-Weight rating on DexCom but lowers the price target from $138 to $113.
The lowered price target from $138 to $113 by Barclays suggests a less optimistic outlook for DexCom's stock performance, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100